FY2025 · period end Dec '25 · from the 10-K filed Feb 13, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0.64B | $0.61B | $0.62B | $0.52B | $0.49B |
| Gross Profit | $0.44B | $0.41B | $0.41B | $0.40B | $0.42B |
| Operating Income | negative: -$0.06B | negative: -$0.19B | negative: -$0.27B | negative: -$0.17B | negative: -$0.05B |
| Net Income | negative: -$0.04B | negative: -$0.18B | negative: -$0.26B | negative: -$0.17B | negative: -$0.06B |
| EPS (Diluted) | negative: -$0.35 | negative: -$1.52 | negative: -$2.18 | negative: -$1.46 | negative: -$0.53 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $1.04B | $0.92B | $0.97B | $1.03B | $1.02B |
| Total Liabilities | $0.25B | $0.21B | $0.22B | $0.22B | $0.20B |
| Stockholders' Equity | $0.80B | $0.71B | $0.74B | $0.81B | $0.82B |
| Cash & Equivalents | — | $0.34B | $0.36B | $0.22B | $0.59B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $0.14B | $0.01B | negative: -$0.02B | negative: -$0.03B | negative: -$0.02B |
| Capital Expenditures | $0.01B | $0.01B | $0.05B | $0.13B | $0.10B |
| Free Cash Flow | $0.13B | negative: -$0.01B | negative: -$0.06B | negative: -$0.17B | negative: -$0.12B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 69.1% | 67.9% | 66.2% | 76.7% | 84.9% |
| Operating Margin | negative: -0.1% | negative: -0.3% | negative: -0.4% | negative: -0.3% | negative: -0.1% |
| Net Margin | negative: -0.1% | negative: -0.3% | negative: -0.4% | negative: -0.3% | negative: -0.1% |
| Return on Equity | negative: -5.8% | negative: -25.2% | negative: -33.0% | negative: -20.5% | negative: -7.5% |
| Return on Assets | negative: -4.4% | negative: -19.4% | negative: -25.6% | negative: -16.2% | negative: -6.0% |
| Debt / Equity | — | — | — | — | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001628280-26-054491 | Jun 30, 2026 | Aug 7, 2026 | Aug 6, 2026 21:31 UTC | EDGAR |
| 8-K | 0001628280-26-054273 | Aug 6, 2026 | Aug 6, 2026 | Aug 6, 2026 20:03 UTC | EDGAR |
| 8-K | 0001628280-26-041651 | Jun 4, 2026 | Jun 8, 2026 | Jun 8, 2026 20:46 UTC | EDGAR |
| 10-Q | 0001628280-26-032388 | Mar 31, 2026 | May 8, 2026 | May 7, 2026 21:36 UTC | EDGAR |
| 8-K | 0001628280-26-032073 | May 7, 2026 | May 7, 2026 | May 7, 2026 20:03 UTC | EDGAR |
| 10-K | 0001628280-26-007822 | Dec 31, 2025 | Feb 13, 2026 | Feb 12, 2026 22:38 UTC | EDGAR |
| 8-K | 0001628280-26-007673 | Feb 12, 2026 | Feb 12, 2026 | Feb 12, 2026 21:09 UTC | EDGAR |
| 8-K | 0001628280-26-001808 | Jan 11, 2026 | Jan 12, 2026 | Jan 12, 2026 20:52 UTC | EDGAR |
Direct links to SEC EDGAR. TXG has additional filings available on the SEC site.
6 numbers 10x Genomics, Inc. later changed — same XBRL tag, both filings linked.
Other Employee-related Liabilities, Current·As of Dec 31, 2021
Major restatementwas$378K
Revised up in a 10-K.
Impairment of Long-Lived Assets Held-for-use·FY 2023
Major restatementwas$4.6M
Revised up in a 10-K.
Other Employee-related Liabilities, Current·As of Dec 31, 2019
Major restatementwas$3.8M
Revised down in a 10-K.
Other Assets, Noncurrent·As of Dec 31, 2020
Major restatementwas$26.7M
Revised down in a 10-K.
Other Liabilities, Noncurrent·As of Dec 31, 2019
Major restatementwas$1.1M
Revised up in a 10-K.
Other Liabilities, Current·As of Dec 31, 2021
Major restatementwas$5.3M
Revised up in a 10-K.
TXG is not the only one.
See every restatement we've found across the market — or get an alert the next time TXG revises a number.
Restatements are detected by comparing every vintage of a fact across all of 10x Genomics, Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows TXG's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling 10x Genomics, Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on TXG yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on TXG and publish the result to your public profile.
Ask about 10x Genomics, Inc.
Continue in Workspace — cited answers on TXG, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs